



Eden Biodesign to offer Millipore's Proprietary Expression Technology as part of its Cell Line Development Services and cGMP Manufacturing of Highly Productive Mammalian Cell Lines

Collaboration Offers a Powerful Combination of cGMP Manufacturing and Ubiquitous Chromatin Opening Elements (UCOE®) Expression Technology

Liverpool, UK; RTP, N.C., USA, and Billerica, Mass., USA – (March 24, 2010) – Eden Biodesign Ltd. and Millipore Corporation today announced a partnership that will provide biopharmaceutical companies with access to a powerful combination of Eden's cGMP manufacturing and Millipore's Ubiquitous Chromatin Opening Elements (UCOE®) expression technology.

As part of this agreement, Eden Biodesign will employ Millipore's proprietary UCOE® expression technology to undertake mammalian cell line development projects and cGMP production for third-party clients.

Millipore's UCOE® technology provides major improvements in gene expression for stably transfected mammalian cells through effects on the structure of chromatin. Cells developed using Millipore's UCOE® technology are stable high-expressors, which means it is much easier and faster for biopharmaceutical manufacturers to identify high-yielding clones with the productivity and stability required for biomanufacturing than with many other expression systems.

“We are delighted to work with a recognized industry leader like Millipore to make this extremely valuable technology available to our clients around the world,” said Roger Lias, Ph.D., president of Eden Biodesign’s North American subsidiary. “Speed-to-clinic and the ability to rapidly develop highly productive cell lines that will support economically viable production through clinical development, process scale-up and steady-state large scale commercial supply are vitally important considerations for our clients.”

“Millipore is committed to bringing innovation that solves critical biopharmaceutical manufacturing business needs. Our distinctive UCOE® technology, with its high expression elements, revolutionizes the speed by which protein therapeutics can be produced in mammalian cells,” said Andrew Bulpin, Ph.D., Vice President, Upstream Processing for Millipore’s Bioprocess Division. “We are pleased to collaborate with Eden Biodesign in the complex mammalian cell development arena and have high expectations for the ongoing success of this partnership.”

About Eden Biodesign

Eden Biodesign is a globally-integrated biopharmaceutical company offering consultancy, biopharmaceutical design, process development and cGMP manufacturing services to leading biotech and pharmaceutical clients around the world. With a reputation for commercializing biopharmaceutical products and processes, the company offers expertise and guidance in multiple sectors. Eden Biodesign’s world class facilities and knowledge in process development, manufacturing, regulatory and technology transfer support ensure that Eden Biodesign offers much more than a traditional CMO. Find out more at www.EdenBiodesign.com.

About Millipore

Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world's challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 5,900 employees worldwide. For more information, please contact Millipore Tech Service at 1-800-548-7853 or 951-676-8080 or visit www.millipore.com.

Safe Harbor Statement

Certain of the matters discussed herein, as well as in future oral and written statements by management of Millipore Corporation that are forward-looking statements, are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements.

Potential risks and uncertainties that could affect Millipore's future operating results include, without limitation, failure to achieve design wins into our pharmaceutical and biotechnology customers' manufacturing design phase for a particular drug or vaccine; delay, suspension or termination of a customer's volume production; fluctuations in the timing of customers' orders; lack of availability of raw materials or component products on a timely basis; regulatory delay in the approval of new therapeutics; limitations on cash flow for operations and investment due to debt service obligations; the inability to establish and maintain necessary product and process quality levels; reduced demand for cell culture products using bovine serum; the inability to realize the expected benefits of development, marketing, licensing and other alliances; competitive factors such as new membrane or chromatography technology; risks relating to our concentration of principal manufacturing operations; the inability to successfully integrate acquired businesses; the inability to utilize technology in current or planned products due to overriding rights by third parties; potential environmental liabilities; conditions in the economy in general and in the bioscience and bioprocess markets in particular; foreign exchange fluctuations; reduced private and government research funding; exposure to product liability

claims; and difficulties inherent in transferring or outsourcing of manufacturing operations. Please refer to our filings with the SEC, including our most recent Annual Report on Form 10-K, for more information on these and other risks that could cause actual results to differ.

#

Media Contacts:

Eden Biodesign

John D. Wagner

Propel Marketing Group

919 796 9984

Jdwagner@PropelMG.com

www.PropelMG.com

Millipore

Janice Paquette

Global Director of Communications

Bioprocess Division

781 533 5197

Janice_Paquette@Millipore.com

www.millipore.com